Investment analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
AEZS stock opened at $3.29 on Friday. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The company’s 50 day moving average price is $2.89 and its two-hundred day moving average price is $3.26. The company has a market capitalization of $5.90 million, a PE ratio of -0.22 and a beta of 1.55.
Aeterna Zentaris Company Profile
Featured Articles
- Five stocks we like better than Aeterna Zentaris
- Comparing and Trading High PE Ratio Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to buy stock: A step-by-step guide for beginners
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.